Biotechnology business and revenue models: The dynamic of technological evolution and capital market ingenuity

The Business of Healthcare Innovation

Volumn , Issue , 2005, Pages 190-222

  Sammut, Stephen M ^a,b  

^a Wharton Entrepreneurial Programs and Health Care Systems   (United States)

^b Burrill and Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82255186749     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511488672.005     Document Type: Chapter

References (7)

1. CIBC World Markets Corporation, “Proteomics Toolbox Technologies,” in Burrill & Company, Biotech 2001: Life Sciences-Genomics, Proteomics and More, 15th edn. (San Francisco, CA: Burrill & Company, 2001), 17, fig. 2.
2. Lehman Brothers, “The ‘Omics’ Development Chain,” in Burrill & Company, Biotech 2001, 19, fig. 3.
3. Burrill & Company, Biotech 2001, 19.
4. Windhover Communications, “Alliances statistics,” in Burrill & Company, Biotech 2004: Biotech Back on Track, 18th edn. (San Francisco, CA: Burrill & Company, 2004), 314-323.
5. Burrill & Company, Biotech 2004.
6. Lawton R. Burns, The Health Care Value Chain (San Francisco, CA: Jossey-Bass, 2002).
7. Windhover Communications as cited in Biotech 2004.